IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: 09/436,347 Group Art Unit: 1643

Confirmation No.: 6491 Examiner: A.M. Harris

Filed: 9 November 1999

Inventor: Christine A. WHITE et al.

For: Treatment of Chronic Lymphocytic Leukemia using Anti-CD20 Antibodies

(as amended)

Mail Stop AF

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

NOTICE OF APPEAL UNDER 37 C.F.R. § 41.31(a)

Sir:

Applicant hereby appeals to the Board of Appeals and Interferences from the decision of the Primary Examiner mailed 17 July 2007, rejecting claims 29-98.

It appears that the outstanding Office action may have been final. *See* reply filed 7 August 2007 at page 10. Applicant renews its request as stated in that paper that the Office clarify the status of the July 2007 action.

The Office action mailed 17 July 2007 set a 3-month period for response. As this notice is filed within the stated period, it is timely.

Applicant requests that the Director debit the appeal fee (\$510, § 41.20(b)(1)) from our Deposit Account No. 18-1260. Any other fees required to render this notice timely or proper may be charged to the same account.

Respectfully submitted,

/David L. Fitzgerald/

David L. Fitzgerald, Reg. No. 47,347 Attorney for Biogen Idec Inc.

SIDLEY AUSTIN LLP 1501 K Street, N.W. Washington, DC 20005 tel. (202) 736-8818 fax (202) 736-8711

BI 0525CP1 17 OCTOBER 2007